Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (6 issues)
Down 1.3% on fading volume (RVOL 0.44) — RSI 25 deeply oversold yet still standing on the 200-day at 159.6, the only name in this oversold batch with the long-term trend intact. Nine analysts see 26.9% upside and the selling looks exhausted; a high-volume up day is the trigger for a starter position. Sidelines today.
A tentative +1.77% bounce: RSI at a deeply oversold 25.9 while still holding above the 200-day (159.4), and 9 analysts see 25% upside after a 22% monthly drop. Oversold plus intact long-term trend is worth watching—waiting for confirmation before committing.
Down 2.91% with RSI at 22.4 and RSI(7) at 12.7 — the most extreme oversold readings on the board — after a 22.8% month. Q2 EPS of $4.02 beat, but full-year guidance at a $14.65 midpoint trails the $14.88 consensus; the issue is margin pressure rather than a one-off. Nine analysts at 27.5% upside — staying flat.
Up 1.72% but with RSI at 24.2 and RSI(7) at 14.5 still the most extreme oversold readings on the board after a 22.7% week; the dialysis collapse hasn't halted. Sidelines.
Down 4.25% with RSI(14) at 21.1 and RSI(7) at 9.2 — the most extreme oversold readings on the board — after weekly and monthly declines of 24.6% and 24.4%, below every moving average. The decline hasn't halted; sidelines.
Down 17% with RSI 23 deeply oversold on a volume flush (relvol 4.4), likely an earnings shock — sidelines until it stabilizes; don't catch the knife.